Related Experiment Video
Updated: Jun 20, 2026
10:28
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
Development and external validation of a machine learning-based model for identifying advanced Parkinson's disease
Xiao-Ru Tan1, Shao-Dan Zhou2, Bing-Hua Lv1
1Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Frontiers in Aging Neuroscience
|June 19, 2026
Summary
A new model using six routine blood biomarkers can reliably identify advanced Parkinson's disease (PD). This non-invasive approach aids timely intervention for patients with advanced PD.
Area of Science:
- Neurology
- Biomarker Discovery
- Machine Learning in Medicine
Background:
- Accurate identification of advanced Parkinson's disease (PD) is critical for effective treatment.
- Current diagnostic methods for PD stage rely on subjective clinical assessments or costly biomarkers.
- There is a need for accessible and objective tools to predict PD progression.
Purpose of the Study:
- To develop and validate a predictive model for advanced PD using machine learning and routine blood tests.
- To identify key blood biomarkers indicative of advanced PD stages.
- To create an economically efficient and non-invasive tool for PD staging.
Main Methods:
- Retrospective analysis of 536 PD patients (discovery) and 80 (validation).
- Classification of patients into early or advanced stages using Hoehn and Yahr scale.
- Application of LASSO and Random Forest algorithms to select predictors from routine blood variables.
- Construction of a predictive model using multivariable logistic regression.
- Evaluation of model performance via AUC, calibration curves, and decision curve analysis (DCA).
Main Results:
- Six routine blood biomarkers (total bilirubin, indirect bilirubin, albumin, cholinesterase, lactate dehydrogenase, creatine kinase) were identified as significant predictors.
- The predictive model achieved high discrimination in the discovery cohort (AUC=0.873) and validation cohort (AUC=0.736).
- The model demonstrated good calibration and clinical utility across various probability thresholds.
- Advanced PD patients showed distinct biomarker profiles compared to early-stage patients.
Conclusions:
- A reliable, non-invasive, and cost-effective predictive model for advanced PD was successfully developed.
- The model leverages readily available blood biomarkers, facilitating wider clinical application.
- This tool supports timely therapeutic interventions for individuals with advanced Parkinson's disease.
Related Concept Videos
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...